The prevalence and clinical significance of 18F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma

Hematological Oncology

Volumn 29, Issue 2, 2011, Pages 67-74

  Lin, Michael ^a,b   Wong, Christine ^a   Lin, Peter ^b   Shon, Ivan Ho ^a,b   Cuganesan, Ramesh ^b   Som, Seu ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b LIVERPOOL HOSPITAL   (Australia)

Author keywords

FDG; Lymphoma; NHL; PET; PET CT; Positron emission tomography; Thyroid

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG UPTAKE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THYROID FOLLICULAR CARCINOMA; THYROID GLAND; THYROID PAPILLARY CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; THYROID GLAND; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79959207910     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.955     Document Type: Article

References (25)

1. Lin M, Ho Shon I, Lin P. Positron emission tomography: current status and future challenges. Intern Med J 2010; 40: 19-29.
2. Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med 2006; 47: 1326-1334.
3. Nakamoto Y, Tatsumi M, Hammoud D, Cohade C, Osman MM, Wahl RL. Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology 2005; 234: 879-885.
4. Chen YK, Chen YL, Cheng RH, Yeh CL, Lee CC, Hsu CH. The significance of FDG uptake in bilateral thyroid glands. Nucl Med Commun 2007; 28: 117-122.
5. Deichen JT, Schmidt C, Prante O, Maschauer S, Papadopoulos T, Kuwert T. Influence of TSH on uptake of [18F]fluorodeoxyglucose in human thyroid cells in vitro. Eur J Nucl Med Mol Imaging 2004; 31: 507-512.
6. Chu Q, Connor MS, Lilien DL, Johnson LW, Turnage RH, Li BDL. Positron emission tomography (PET) positive thyroid incidentaloma: the risk of malignancy observed in a tertiary referral center. Am Surg 2006; 72: 272-275.
7. Kang KW, Kim SK, Kang HS, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 2003; 88: 4100-4104.
8. Ansell SM, Grant CS, Habermann TM. Primary thyroid lymphoma. Semin Oncol 1999; 26: 316-323.
9. Wang SA, Rahemtullah A, Faquin WC, Roepke J, Harris NL, Hasserjian RP. Hodgkin's lymphoma of the thyroid: a clinicopathologic study of five cases and review of the literature. Mod Pathol 2005; 18: 1577-1584.
10. Glass AG, Karnell LH, Menck HR. The National Cancer Data Base Cancer Society Report on non-Hodgkin's lymphoma. Cancer 1997; 80: 2311-2320.
11. Cohen MS, Arslan N, Dehdashti F, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 2001; 130: 941-946.
12. Bogsrud TV, Karantanis D, Nathan MA, et al. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Commun 2007; 28: 373-381.
13. Choi JY, Lee KS, Kim HJ, et al. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization. J Nucl Med 2006; 47: 609-615.
14. Schiepers C, Filmont JE, Czernin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003; 30 (Suppl. 1): S82-S88.
15. Scott AM, Gunawardana DH, Wong J, et al. Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging 2009; 36: 347-353.
16. Are C, Hsu JF, Schoder H, Shah JP, Larson SM, Shaha AR. FDG-PET detected thyroid incidentalomas: need for further investigation? Ann Surg Oncol 2007; 14: 239-247.
17. Wang W, Larson SM, Fazzari M, et al. Prognostic value of [18F] fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000; 85: 1107-1113.
18. Matsuzu K, Segade F, Matsuzu U, Carter A, Bowden DW, Perrier ND. Differential expression of glucose transporters in normal and pathologic thyroid tissue. Thyroid 2004; 14(10): 806-812.
19. Are C, Hsu JF, Ghossein RA, Schoder H, Shah JP, Shaha AR. Histological aggressiveness of fluorodeoxyglucose positron-emission tomogram (FDG-PET)-detected incidental thyroid carcinomas. Ann Surg Oncol 2007; 14(11): 3210-3215.
20. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. The American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19(11): 1167-1214.
21. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 2007; 25: 571-578.
22. Kasamon YL, Jones RJ, Wahl RL. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med 2007; 48: 19S-27S.
23. Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med 2009; 50: 21S-30S.
24. Samih N, Hovsepian S, Aouani A, Lombardo D, Fayet G. Glut-1 translocation in FRTL-5 thyroid cells: role of phosphatidylinositol 3-kinase and N-glycosylation. Endocrinology 2000; 141: 4146-4155.
25. Karantanis D, Bogsrud TV, Wiseman GA, et al. Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J Nucl Med 2007; 48: 896-901.